Do analysts recommend VTVT or ADXS?

vTv Therapeutics currently has a consensus price target of $55.83, suggesting a potential upside of 68.99%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 2 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VTVT or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% Ayala Pharmaceuticals N/A N/A N/A

Do analysts recommend ADXS or UNCY?

Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 335.00%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Unicycive Therapeutics 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is ADXS or UNCY more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Unicycive Therapeutics N/A -134.69% -84.51%

Do analysts rate ADXS or NRXP?

NRx Pharmaceuticals has a consensus price target of $34.50, indicating a potential upside of 914.71%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ADXS or NRXP more profitable?

Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A NRx Pharmaceuticals N/A N/A -202.92%

Do analysts rate VANI or ADXS?

Vivani Medical currently has a consensus target price of $3.75, indicating a potential upside of 169.78%. Given Vivani Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Vivani Medical is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivani Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VANI or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Vivani Medical's return on equity. Company Net Margins Return on Equity Return on Assets Vivani Medical N/A -264.04% -79.85% Ayala Pharmaceuticals N/A N/A N/A

Do analysts rate CPIX or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 08/10/2026

Compare

ADXS vs. VTVT, UNCY, NRXP, VANI, and CPIX

Should you buy Ayala Pharmaceuticals stock or one of its competitors? Ayala Pharmaceuticals's main competitors and comparable companies include vTv Therapeutics (VTVT), Unicycive Therapeutics (UNCY), NRx Pharmaceuticals (NRXP), Vivani Medical (VANI), and Cumberland Pharmaceuticals (CPIX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

vTv Therapeutics has higher revenue and earnings than Ayala Pharmaceuticals. vTv Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$36.84M	3.53	-$26.97M	-$1.06	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Ayala Pharmaceuticals' return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Ayala Pharmaceuticals	N/A	N/A	N/A

vTv Therapeutics currently has a consensus price target of $55.83, suggesting a potential upside of 68.99%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe vTv Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

vTv Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

In the previous week, vTv Therapeutics had 18 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 18 mentions for vTv Therapeutics and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat vTv Therapeutics' score of -0.54 indicating that Ayala Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
vTv Therapeutics	Negative
Ayala Pharmaceuticals	Neutral

Summary

vTv Therapeutics beats Ayala Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 335.00%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Unicycive Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Unicycive Therapeutics has lower revenue, but higher earnings than Ayala Pharmaceuticals. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Unicycive Therapeutics	$680K	201.40	-$26.56M	-$2.21	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Unicycive Therapeutics	N/A	-134.69%	-84.51%

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Unicycive Therapeutics and 0 mentions for Ayala Pharmaceuticals. Unicycive Therapeutics' average media sentiment score of 0.62 beat Ayala Pharmaceuticals' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
Unicycive Therapeutics	Positive

Summary

Unicycive Therapeutics beats Ayala Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to NRx Pharmaceuticals?

Ayala Pharmaceuticals (NASDAQ:ADXS) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

NRx Pharmaceuticals has a consensus price target of $34.50, indicating a potential upside of 914.71%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

NRx Pharmaceuticals has lower revenue, but higher earnings than Ayala Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
NRx Pharmaceuticals	$1.23M	100.15	-$28.62M	-$1.09	N/A

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
NRx Pharmaceuticals	N/A	N/A	-202.92%

Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, NRx Pharmaceuticals had 11 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 11 mentions for NRx Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Ayala Pharmaceuticals' average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -0.01 indicating that Ayala Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Ayala Pharmaceuticals	Neutral
NRx Pharmaceuticals	Neutral

Summary

NRx Pharmaceuticals beats Ayala Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Vivani Medical?

Vivani Medical (NASDAQ:VANI) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

6.8% of Vivani Medical shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 53.3% of Vivani Medical shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Vivani Medical has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market.

In the previous week, Vivani Medical had 7 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 7 mentions for Vivani Medical and 0 mentions for Ayala Pharmaceuticals. Vivani Medical's average media sentiment score of 0.54 beat Ayala Pharmaceuticals' score of 0.00 indicating that Vivani Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Vivani Medical	Positive
Ayala Pharmaceuticals	Neutral

Vivani Medical currently has a consensus target price of $3.75, indicating a potential upside of 169.78%. Given Vivani Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Vivani Medical is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivani Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vivani Medical has higher earnings, but lower revenue than Ayala Pharmaceuticals. Vivani Medical is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivani Medical	N/A	N/A	-$26.61M	-$0.40	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Ayala Pharmaceuticals' return on equity of 0.00% beat Vivani Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivani Medical	N/A	-264.04%	-79.85%
Ayala Pharmaceuticals	N/A	N/A	N/A

Summary

Vivani Medical beats Ayala Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

In the previous week, Cumberland Pharmaceuticals had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Cumberland Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 1.13 beat Ayala Pharmaceuticals' score of 0.00 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Cumberland Pharmaceuticals	Positive
Ayala Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cumberland Pharmaceuticals has higher revenue and earnings than Ayala Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.68	-$2.84M	-$0.71	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Ayala Pharmaceuticals has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Ayala Pharmaceuticals' return on equity of 0.00% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-34.40%	-26.77%	-8.97%
Ayala Pharmaceuticals	N/A	N/A	N/A

Cumberland Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Cumberland Pharmaceuticals beats Ayala Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.79M	$12.02B	$7.08B	$12.96B
Dividend Yield	N/A	2.69%	2.57%	10.34%
P/E Ratio	-0.08	783.52	268.40	25.05
Price / Sales	11.05	749.62	558.69	69.51
Price / Cash	N/A	70.00	72.26	50.42
Price / Book	-0.29	10.56	13.21	6.18
Net Income	-$48.07M	$2.78B	$3.44B	$347.05M
7 Day Performance	N/A	0.52%	2.07%	1.24%
1 Month Performance	N/A	-1.50%	-0.26%	-0.65%
1 Year Performance	N/A	165.83%	70.32%	20.12%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
VTVT vTv Therapeutics	2.8423 of 5 stars	$35.59 +2.8%	$55.83 +56.9%	+119.8%	$140.23M	$1.02M	N/A	9	Earnings Report Analyst Revision High Trading Volume
UNCY Unicycive Therapeutics	3.1954 of 5 stars	$5.11 +1.1%	$21.75 +326.1%	+24.7%	$139.83M	$680K	N/A	9	Upcoming Earnings
NRXP NRx Pharmaceuticals	2.2423 of 5 stars	$3.58 +15.7%	$34.50 +865.0%	+46.6%	$129.31M	$1.23M	N/A	2	Positive News Upcoming Earnings Analyst Forecast High Trading Volume
VANI Vivani Medical	3.5642 of 5 stars	$1.44 +5.5%	$3.75 +161.3%	+10.3%	$123.75M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. VTVT, UNCY, NRXP, VANI, and CPIX

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to NRx Pharmaceuticals?

Summary

How does Ayala Pharmaceuticals compare to Vivani Medical?

Summary

How does Ayala Pharmaceuticals compare to Cumberland Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. VTVT, UNCY, NRXP, VANI, and CPIX

How does Ayala Pharmaceuticals compare to vTv Therapeutics?

Which has better valuation and earnings, VTVT or ADXS?

Do institutionals & insiders hold more shares of VTVT or ADXS?

Is VTVT or ADXS more profitable?

Do analysts recommend VTVT or ADXS?

Which has more risk & volatility, VTVT or ADXS?

Does the media refer more to VTVT or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Unicycive Therapeutics?

Do institutionals and insiders have more ownership in ADXS or UNCY?

Do analysts recommend ADXS or UNCY?

Which has stronger valuation and earnings, ADXS or UNCY?

Is ADXS or UNCY more profitable?

Which has more volatility & risk, ADXS or UNCY?

Does the media favor ADXS or UNCY?

Summary

How does Ayala Pharmaceuticals compare to NRx Pharmaceuticals?

Do analysts rate ADXS or NRXP?

Which has higher earnings and valuation, ADXS or NRXP?

Is ADXS or NRXP more profitable?

Which has more volatility and risk, ADXS or NRXP?

Do institutionals and insiders hold more shares of ADXS or NRXP?

Does the media favor ADXS or NRXP?

Summary

How does Ayala Pharmaceuticals compare to Vivani Medical?

Do insiders and institutionals have more ownership in VANI or ADXS?

Which has more risk & volatility, VANI or ADXS?

Does the media favor VANI or ADXS?

Do analysts rate VANI or ADXS?

Which has higher valuation and earnings, VANI or ADXS?

Is VANI or ADXS more profitable?

Summary

How does Ayala Pharmaceuticals compare to Cumberland Pharmaceuticals?

Does the media favor CPIX or ADXS?

Do analysts rate CPIX or ADXS?

Which has preferable earnings & valuation, CPIX or ADXS?

Is CPIX or ADXS more profitable?

Which has more risk and volatility, CPIX or ADXS?

Do insiders & institutionals have more ownership in CPIX or ADXS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools